Drug Profile
Rotavirus vaccine trivalent - China National Biotec Group
Alternative Names: Trivalent genetic reassortment vaccineLatest Information Update: 11 Oct 2021
Price :
$50
*
At a glance
- Originator China National Biotec Group
- Class Rotavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rotavirus infections
Most Recent Events
- 11 Oct 2021 No development reported - Phase-III for Rotavirus infections (Prevention) in China (PO)
- 05 Sep 2018 Phase III development in Rotavirus infections is ongoing in China (China National Biotec Group pipeline, September 2018)